Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesTransglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
Journal of Cancer Research & Clinical Oncology, 09/25/09
Park K-S et al. – Good responders of cisplatin in NSCLC could be identified by the promoter methylation of TGM2 and that TGase 2 inhibition appears to be an effective cisplatin-sensitizing modality in NSCLC.
Methods- TGM2 promoter methylation was analyzed by sodium bisulfite sequencing
- Cisplatin sensitivity was analyzed by treatment of cisplatin in NSCLC cell lines with/without TGM2 or TGM2 siRNA transfection
- In one-third of NSCLC cell lines, TGase 2 gene (TGM2) was silenced by promoter methylation
- The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195)
- Down-regulation and over-expression of TGM2 in those NSCLC cells also suggested a positive correlation of cisplatin sensitivity and TGM2 inhibition. With doxorubicin, the relationship was quite similar
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Stage I nonsmall cell lung cancer in patients aged >=75 years
Cancer, 12/11/09
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
European Journal of Cancer, 12/11/09
Tissue diagnosis of new lung nodules in patients with a known malignancy
The American Journal of Surgery, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor